Site Tools
User Tools
Differences
This shows you the differences between two versions of the page.
|
start [2016/10/16 14:53] f.demichelis@unitn.it |
start [2017/06/06 15:46] (current) f.demichelis@unitn.it |
||
|---|---|---|---|
| Line 4: | Line 4: | ||
| The laboratory integrates computational and experimental work and is characterized by inter-disciplinary/inter-institutional collaborations that allow for a challenging and stimulating atmosphere and state-of-the-art approaches. | The laboratory integrates computational and experimental work and is characterized by inter-disciplinary/inter-institutional collaborations that allow for a challenging and stimulating atmosphere and state-of-the-art approaches. | ||
| + | |||
| + | Follow us on {{:twitter.png?30|[[https://twitter.com/FrancescaBZNY]]}} | ||
| <html> | <html> | ||
| - | <span style="color:white;font-size:150%;background-color:#0066FF;font-weight: bold;"> | + | <span style="color:white;font-size:150%;background-color:#00fffa;font-weight: bold;"> |
| news and notices from our group | news and notices from our group | ||
| </span> | </span> | ||
| </html> | </html> | ||
| + | |||
| + | **June 5th 2017**: **ASCO 2017** Whole exome sequencing of circulating tumor DNA (ctDNA) in patients with neuroendocrine prostate cancer presented at ASCO 2017 was featured in UroToday. Collaboration with Weill Cornell Medicine.([[https://www.urotoday.com/conference-highlights/asco-2017/asco-2017-prostate-cancer/96283-asco-2017-whole-exome-sequencing-of-circulating-tumor-dna-ctdna-in-patients-with-neuroendocrine-prostate-cancer-informs-tumor-heterogeneity.html|article]]). | ||
| + | |||
| + | ---- | ||
| + | {{ :nature_genetics.jpg?nolink&130}} | ||
| + | **October 17th 2016**: [[http://www.nature.com/ng/journal/vaop/ncurrent/full/ng.3692.html|Clonal Evolution of Chemotherapy-resistant Urothelial Carcinoma]] Chemotherapy drives treatment resistance in bladder cancer as revealed by allele-specific CLONET based analysis of bladder cancer tissues. An international team-science collaborative work with Weill Cornell Medicine and the Englander Institute for Precision Medicine ([[http://weill.cornell.edu/news/news/2016/10/chemotherapy-drives-treatment-resistance-in-bladder-cancer.html|press release]]). | ||
| + | |||
| + | ---- | ||
| **October 10th 2016**: [[http://www.cell.com/cancer-cell/fulltext/S1535-6108(16)30440-8|N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer]] A study from David Rickman's group with our collaboration published in Cancer Cell. | **October 10th 2016**: [[http://www.cell.com/cancer-cell/fulltext/S1535-6108(16)30440-8|N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer]] A study from David Rickman's group with our collaboration published in Cancer Cell. | ||
| ---- | ---- | ||
| - | {{ :nature_biotechnology.jpg?150}} | + | {{ :nature_biotechnology.jpg?nolink&150}} |
| **March 10th 2016**: [[http://www.nature.com/nbt/journal/v34/n3/full/nbt.3502.html|Voices of biotech]] **Nature Biotechnology** asks a selection of researchers about the most exciting frontier in their field and the most needed technologies for advancing knowledge and applications. | **March 10th 2016**: [[http://www.nature.com/nbt/journal/v34/n3/full/nbt.3502.html|Voices of biotech]] **Nature Biotechnology** asks a selection of researchers about the most exciting frontier in their field and the most needed technologies for advancing knowledge and applications. | ||
| Line 32: | Line 42: | ||
| ---- | ---- | ||
| - | {{ :erc_logo2.png?150|}} | + | {{ :erc_logo2.png?nolink&150|}} |
| **European Research Council Consolidator grant was awarded to F Demichelis:**\\ | **European Research Council Consolidator grant was awarded to F Demichelis:**\\ | ||
| Synthetic Lethal Phenotype Identification through Cancer Evolution Analysis (SPICE) | Synthetic Lethal Phenotype Identification through Cancer Evolution Analysis (SPICE) | ||